Almirall 'Shared Skin' dermatology disease awareness campaign gets employees involved

Almirall

Almirall's  dermatology focus will get a boost with a new skin disease awareness campaign. The Barcelona-based pharma’s digital work called the “Shared Skin Initiative” features 5 Almirall employees made up with various skin conditions to show the emotional impact of dermatological diseases.

The campaign was originally meant to be internal-only, an Almirall spokeswoman said via email. However, after a positive and successful reception from employees, Almirall decided to make the work public. Almirall sent the videos to journalists and it can also be seen on YouTube and LinkedIn.

The pharma wanted to bring “Almirall´s employees closer to dermatological diseases and make them share their skin to empathise, even more, with those who suffer of skin diseases.”

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Almirall refocused on dermatology in late 2014 after selling its respiratory business to AstraZeneca. The pharma markets a variety of treatments for dermatological conditions such as psoriasis, dermatitis and severe acne as well as aesthetic skin treatments. It most recently acquired the rights to Veltin and Altavax from GlaxoSmithKline’s Stiefel and will market them through its U.S. affiliate Aqua Pharmaceuticals, which it acquired at the end of 2013.

The new campaign is not tied to any specific introduction of drugs, the spokeswoman said, but rather is it is “more of an overall boosting effort to reinforce Almirall’s global strategy focused on dermatology.”

- see the video

Related Articles:
Almirall inks deal with startup Bicosome for its skin delivery technology
Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout
AstraZeneca seals the deal for Almirall's respiratory meds
Almirall buys ready-made dermatology R&D operation in €365M deal

Read more on

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.